Evidence map›Paper›PMID 39478631›Full record

ArticleRadiation oncology (London, England)2024

Tissue microarray analyses of the essential DNA repair factors ATM, DNA-PKcs and Ku80 in head and neck squamous cell carcinoma.

Henrike Barbara Zech, Clara von Bargen, Agnes Oetting, Nikolaus Möckelmann, Christina Möller-Koop, Melanie Witt, Nina Struve, Cordula Petersen, Christian Betz, Kai Rothkamm and 3 more

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Clinical stage-dependent expression of MRE11 and its association with laryngeal cancer progression.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Henrike Barbara ZechDepartment of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Clara von BargenInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Agnes OettingDepartment of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nikolaus MöckelmannDepartment of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christina Möller-KoopInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Melanie WittInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nina StruveDepartment of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Cordula PetersenDepartment of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian BetzDepartment of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kai RothkammDepartment of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Adrian MünscherDepartment of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till Sebastian Clauditz *Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorsten Rieckmann *Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. t.rieckmann@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) negative for Human Papillomavirus (HPV) has remained a difficult to treat entity, whereas tumors positive for HPV are characterized by radiosensitivity and favorable patient outcome. On the cellular level, radiosensitivity is largely governed by the tumor cells` ability to repair radiation-induced DNA double-strand breaks (DSBs), but no biomarker is established that could guide clinical decision making. Therefore, we tested the impact of the expression levels of ATM, the central kinase of the DNA damage response as well as DNA-PKcs and Ku80, two major factors in the main DSB repair pathway non-homologous end joining (NHEJ).

methodsA tissue microarray of a single center HNSCC cohort was stained for ATM, DNA-PKcs and Ku80 and the expression scored based on staining intensity and the percentages of tumor cells stained. Scores were correlated with clinicopathological parameters and survival.

resultsSamples from 427 HNSCC patients yielded interpretable stainings and were scored following an established algorithm. The majority of tumors showed strong expression of both NHEJ factors, whereas the expression of ATM varied more. The expression scores of ATM and DNA-PKcs were not associated with patient survival. For HPV-negative HNSCC, the minority of tumors without strong Ku80 expression trended towards superior survival when treatment included radiotherapy. Focusing stronger on staining intensity to define the subgroup with lowest and therefore potentially insufficient expression levels in the HPV-negative subgroup, we observed significantly better overall survival for patients treated with radiotherapy but not with surgery alone.

conclusionsOur data suggest that HPV-negative HNSCC with particularly low Ku80 expression represent a highly radiosensitive subpopulation. Confirmation in independent cohorts is required.

Indexed as

Ataxia Telangiectasia Mutated ProteinsDNA-Activated Protein KinaseHead and Neck NeoplasmsKu AutoantigenSquamous Cell Carcinoma of Head and NeckTissue Array AnalysisAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellDNA RepairFemaleHumansMaleMiddle AgedAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkers, TumorDNA-Activated Protein KinaseKu AutoantigenNuclear ProteinsPRKDC protein, humanATMDNA-PKcsDNA repairHNSCCKu80Non-homologous endjoiningPrognostic markerTissue microarray

Identifiers

PMID39478631
PMCPMC11523811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.